Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
9989.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Share Statistics
| Market cap | - |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 1.70% |
|---|---|
| Return on Assets | 1.23% |
| Return on Invested Capital | 2.36% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | - |
| Debt to Equity | 0.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
$0.09
Average shareholder expectationRevenue Estimate
$1.60 B
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$0.22
Average shareholder expectationRevenue Estimate
$2.99 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
2,150 employees
CEO: Li Li Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is an international pharmaceutical enterprise specializing in the production and commercialization of medicinal products. Its operations span Hong Kong, the United States, Europe, Mainland...